


PERSONAL INFORMATION

Matteo Landriscina

 Department of Medical and Surgical Science
University of Foggia
Via Napoli 121, 71122 Foggia

 39 0881 736426  39 3404133018

 matteo.landriscina@unifg.it

 <https://www.unifg.it/it/rubrica/matteo-landriscina> Scopus Author's ID 6603715531

Sex M | Date of birth 24/10/1968 | Nationality Italian

Current Position: Full Professor of Medical Oncology (MED/06)

PhD awarded less than 10 Years ago: No

Scientific Profile: Prof. Landriscina is a senior researcher with has a long-lasting experience in translational studies in Medical and Molecular Oncology. He spent three years in the laboratory of Dr. Thomas Maciag at the Maine Medical Center Research Institute, USA to study the molecular mechanisms of FGF1 and IL1 α secretion, two growth factors involved in angiogenesis, immune response and inflammation with evaluation of their role in cancer, as potential therapeutic targets. His present research topic is the study of the molecular mechanisms responsible for drug resistance in human malignancies with the aim to identify novel therapeutic strategies to improve the efficacy of treatments and characterize novel molecular targets. He is involved in studying the role of TRAP1/HSP90 pathway in inducing resistance to apoptosis and anticancer agents in human malignancies (i.e., colorectal, breast, ovarian and thyroid carcinomas). Prof. Landriscina received research grants from the Italian Association of Cancer Research (AIRC), Lega Italiana per la Lotta ai Tumori (LILT Foundation), Italian Ministry of Education and University (PRIN), Berlucci Foundation and Regione Puglia. He is Director of the Medical Oncology and Biomolecular Therapy Unit at the Policlinico Riuniti University Hospital, being directly involved in clinical management of oncology patients, with specific focus on gastrointestinal and genitourinary cancers.

GOLDEN PARAGRAPH

Bibliometric Indicators:

Publications: 125; # Citations 3933; H index 35; H Index (5 y) 13

3 most relevant publications:

- 1) Sciamanna et al, Reverse Transcriptase inhibitors antagonize the growth of human tumors in vitro and in vivo. *Oncogene* 2005; 24:3923-3931.
- 2) Landriscina M, et al, TRAP1 and the calcium binding protein Sorcin interact in mitochondria and protect cells against apoptosis induced by antitubercular agents. *Cancer Research* 2010; 70(16):6577-6586.
- 3) Maddalena F, et al, Sorcin induces a drug-resistant phenotype in human colorectal cancer through by modulating Ca²⁺ homeostasis. *Cancer Research* 2011; 71(24):7659-7669.

ROLE IN THE PROJECT

Prof. Landriscina's research group has a long-lasting expertise in the field of cancer biology and clinical oncology with a strong background in preclinical/translational studies, tumor molecular characterization and identification of cancer biomarkers. The research group includes scientists with a complementary expertise ranging from medical oncology to molecular biology. The laboratory expertise spans molecular and cellular biology, covering areas of cell culture, gene and protein expression, functional assays for cell viability, flow cytometry, confocal microscopy, extracellular vesicles obtained from cancer cells, next-generation sequencing and liquid biopsy. His ongoing collaborations at research and academic levels includes those with Prof. Franca Esposito (University of Naples, Italy), Prof. Paola Chiarugi (University of Florence, Italy), Dr. Igor Prudovsky (Maine Medical Center Research Institute, USA), Dr. Ugo De Giorgi (IRST Meldola, Italy). His role in the project will be to identify/validate novel candidate biomarkers involved in prostate cancer predisposition and progression. Genomic, transcriptomic, proteomic and epigenomic data obtained from tumor biopsies and circulating tumor DNA will be combined to predict outcomes during management of patients affected by prostate cancer.

WORK EXPERIENCE

2020, July - current

Full Professor of Medical Oncology
Department of Medical and Surgical Sciences, University of Foggia, Italy
Main duties/responsibilities: Lecturer, Principal Investigator
Sector: Academic sector

2019, January - current

Director of the Unit of Medical Oncology and Biomolecular Therapy
University Hospital "Policlinico Riuniti", Foggia, Italy
Main duties/responsibilities: Unit Director
Sector: Health sector

2011, February – now

Translational Research Laboratory – Unit of Solid Tumors
IRCCS-CROB of Rionero in Vulture, Italy
Main duties/responsibilities: Principal Investigator
Sector: Research

2016, July – 2020, June

Associate Professor of Medical Oncology
Department of Medical and Surgical Sciences, University of Foggia, Italy
Main duties/responsibilities: Lecturer, Principal Investigator
Sector: Academic sector

2004, January – 2016, June

Assistant Professor of Medical Oncology
Department of Medical and Surgical Sciences, University of Foggia, Italy
Main duties/responsibilities: Lecturer, Principal Investigator
Sector: Academic sector

2004, January – 2018, December

Medical Oncologist at the Unit of Medical Oncology
University Hospital "Policlinico Riuniti", Foggia, Italy
Main duties/responsibilities: Medical Oncologist
Sector: Health sector

2002, November – 2004, January

Medical Oncologist at the Unit of Medical Oncology
Catholic University, University Hospital "Policlinico Gemelli", Rome, Italy
Main duties/responsibilities: Medical Oncologist
Sector: Health sector

EDUCATION AND TRAINING

1999-2002

PhD in Oncology
 Catholic University, Rome, Italy
 Thesis title: "Molecular mechanisms of angiogenesis"

1998-2001

Postdoctoral Fellowship
 Center for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, Maine, USA
 Main topic: Molecular mechanisms of angiogenesis.

1993-1997

Residency in Oncology
 Catholic University, University Hospital "Policlinico Gemelli", Rome, Italy
 Main topic: Tumor angiogenesis

1987-1993

Degree in Medicine and Surgery
 Catholic University, University Hospital "Policlinico Gemelli", Rome, Italy

 PERSONAL SKILLS

Organisational / managerial skills

Currently responsible for a team of 15 people among researchers, medical oncologists, thesis students, PhD students (University of Foggia) and for research team of 5 researchers (IRCCS CROB of Rionero in Vulture).

 ADDITIONAL INFORMATION

Most 10 relevant publications in the last 10 Years

1. Amoroso MR, Matassa DS, Laudiero G, Egorova AV, Polishchuk RS, Maddalena F, Piscazzi A, Paladino S, Samataro D, Garbi C, ***Landriscina M**, Esposito F (*co-corresponding author). TRAP1 and the proteasome regulatory particle TBP7/Rpt3 interact in the endoplasmic reticulum and control cellular ubiquitination of specific mitochondrial proteins. **Cell Death and Differentiation** 2012; 19(4):592-604. Q1
2. Piscazzi A, Costantino E, Maddalena F, Natalicchio I, Gerardi AMT, Antonetti R, Cignarelli M, **Landriscina M**. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. **Journal of Clinical Endocrinology and Metabolism**, 2012; 97(6):E898-906. Q1
3. Sciacovelli M, Guzzo G, Morello V, Frezza C, Zheng L, Nannini N, Calabrese F, Laudiero G, Esposito F, **Landriscina M**, Defilippi P, Bernardi P, Rasola A. The mitochondrial chaperone TRAP1 promotes neoplastic growth by inhibiting succinate dehydrogenase. **Cell Metabolism** 2013; 17(6):988-99. Q1
4. Condelli V, Piscazzi A, Sisinni L, Matassa DS, Maddalena F, Lettini G, Simeon V, Palladino G, Amoroso MR, Trino S, Esposito F, **Landriscina M**. TRAP1 is involved in BRAF regulation and downstream attenuation of ERK phosphorylation and cell-cycle progression: a novel target for BRAF-mutated colorectal tumors. **Cancer Research** 2014; 74(22):6693-704. Q1
5. Matassa DS, Amoroso MR, Lu H, Avolio R, Arzeni D, Procaccini C, Faicchia D, Maddalena F, Simeon V, Agliarulo I, Zanini E, Mazzoccoli C, Recchi C, Stronach E, Marone G, Gabra H, Matarese G, **Landriscina M***, Esposito E (*co-corresponding author). Oxidative metabolism drives metainflammation-induced platinum resistance in ovarian cancer. **Cell Death and Differentiation** 2016;23(9):1542-54. Q1
6. Lettini G, Sisinni L, Condelli V, Matassa DS, Simeon V, Maddalena F, Gemei M, Lopes E, Vita G, Del Vecchio L, Esposito F, **Landriscina M**. TRAP1 regulates stemness through Wnt/ β -Catenin pathway in human colorectal carcinoma. **Cell**

- Death and Differentiation**, 2016;23(11):1792-1803. Q1
7. Sisinni L, Maddalena F, Condelli V, Pannone G, Simeon V, Lopes V, Li Bergolis V, Piscazzi A, Matassa DS, Mazzoccoli C, Nozza F, Lettini G, Amoroso MR, Bufo P, Esposito F, **Landriscina M**. TRAP1 controls cell cycle progression through the regulation of CDK1 and MAD2 expression/ubiquitination in human breast, colon and lung carcinomas. **Journal of Pathology** 2017, 243(1):123-134. Q1
 8. Notarangelo T, Sisinni L, Trino S, Calice G, Simeon, **Landriscina M**. IL6/STAT3 axis mediates resistance to BRAF inhibitors in thyroid carcinoma cells. **Cancer Letters**, 2018; 433:147-155. Q1
 9. Maddalena F, Condelli V, Matassa DS, Pacelli C, Scrima R, Lettini G, Li Bergolis V, Pietrafesa M, Crispo F, Piscazzi A, Storto G, Capitanio N, Esposito F, **Landriscina M**. TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas. **Molecular Oncology** 2020;14(12):3030-3047. Q1
 10. Condelli V, Calice G, Cassano A, Basso M, Rodriquenz MG, Zupa A, Maddalena F, Crispo F, Pietrafesa M, Aieta M, Sgambato A, Tortora G, Zoppoli P, **Landriscina M**. Novel Epigenetic Eight-Gene Signature Predictive of Poor Prognosis and MSI-Like Phenotype in Human Metastatic Colorectal Carcinomas. **Cancers** 2021, 13, 158. Q1

Projects/Grants

2021-2022

Lega Italiana per la Lotta ai Tumori (LILT)

Targeting metabolic dysregulation to bypass immune escape in human colorectal carcinoma – P.I.

100.000 EUROS

2016-2018

Italian Association of Cancer Research (AIRC) - IG16738

Cancer type-specific regulation of cell metabolism by TRAP1: impact on malignant phenotypes and drug resistance/design – P.I.

330.000 EUROS

2012-2015

Italian Ministry of Health. Young Researchers 2010 Grant - GR-2010-2310057

The role of TRAP1 in the resistance to anti-EGFR1 agents in human colorectal carcinoma – Co-P.I.

220.000 EUROS

2013-2015

Italian Association of Cancer Research (AIRC) - IG13128

TRAP1 controls stress-adaptive responses of cancer cells: a novel molecular target in drug resistance – P.I.

330.000 EUROS

2010-2012

Italian Association of Cancer Research (AIRC) – IG8780

Role of TRAP1, a novel antiapoptotic gene, in the resistance to anticancer therapy in colon and breast tumors – P.I.

195.000 EUROS

2010-2011

Italian Ministry of Education and University – PRIN 20105EH5NS_003

The role of TRAP1 in favoring the resistance to anticancer agents in human breast and colorectal tumors – Co-P.I.

120.000 EUROS

2009-2010

Fondazione Guido Berlucci

Role of the mitochondrial chaperone TRAP1 in the resistance to anticancer agents which inhibit the signaling of EGFR superfamily receptor” – P.I.

110.000 EUROS

2009-2011

Lega Italiana per la Lotta ai Tumori (LILT)

Novel biomarkers for the early diagnosis of non-medullary familial thyroid carcinomas – Co-P.I.

65.000 EUROS

2004-2005

Italian Ministry of Education and University – PRIN 2004054004_002

Redox-dependent mechanisms involved in the regulation of human thyroid and brain tumors – Co-P.I.

35.300 EUROS

Conferences**Most relevant Oral Communications**

- 31th Annual Meeting of the European Thyroid Association, Naples, Italy, 2006
- XXVII Italian Endocrinology Meeting Pisa, June 2008 (Plenary Session)
- National Meeting of the University Medical Oncology College (COMU), Naples. September 2012.
- 6^o Meeting of Italian Thyroid Association, Foggia, December 2012
- European Cancer Congress 2014 (ESMO 2014), September 2014, Madrid.
- EACR-AACR-SIC Special Conference on “Anticancer Drug Action and Drug Resistance: from Cancer Biology to the Clinic”, Florence, June 2015
- ASCO 2015 Gastrointestinal Cancer Symposium, San Francisco, January 2015.
- ESMO 19th World Congress on Gastrointestinal Cancer, Barcelona, July 2017
- ESMO 2017 Congress, Madrid, Spain, September 2017

Honours and awards

- Prize “T. Terranova” for the best MD thesis on Oncological, Catholic University, Italy, 1994.
- Prize for the best oral presentation to the XXIII Italian Meeting on Thyroid Diseases, Turin, Italy, 2005

According to law 679/2016 of the Regulation of the European Parliament of 27th April 2016, I hereby express my consent to process and use my data provided in this CV

Foggia, 30/04/2022

Prof. Matteo Landriscina

